New weight loss pill beats oral Ozempic in major trial
A new oral weight-loss drug, orforglipron, has shown superior efficacy in clinical trials compared to existing injectable options like Ozempic. This development could address patient needle phobia and supply chain issues associated with current GLP-1 medications.
Why it matters
Oral alternatives could significantly increase the accessibility and adoption of weight-loss treatments, impacting the global pharmaceutical market.
A new type of daily pill has proven more effective for weight loss and blood sugar control than its currently available counterparts, according to a recent trial. The drug, known as orforglipron, could be a game-changer in the rapidly expanding oral weight-loss drug market.
The article provides a technical overview of medical trial results and market implications without taking a stance on the drugs themselves.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in